Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Phase 3 Active not recruiting

125 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05257083 2026-03-17

CARTITUDE-6

Phase 3 Active not recruiting

759 enrolled

Plasma cell

Multiple Myeloma

NCT07393282 2026-03-16

LINKER-SMM2

Phase 3 Not yet recruiting

270 enrolled

Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT05827016 2026-03-13

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Phase 3 Recruiting

1,216 enrolled

Plasma cell

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

380 enrolled

Plasma cell

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

Phase 3 Recruiting

795 enrolled

Plasma cell

Multiple Myeloma

NCT07391657 2026-03-12

DURGA-4

Phase 3 Recruiting

508 enrolled

Plasma cell

Multiple Myeloma

NCT05730036 2026-03-06

LINKER-MM3

Phase 3 Recruiting

410 enrolled

Plasma cell

Multiple Myeloma

NCT06045806 2026-03-05

KarMMa-9

Phase 3 Active not recruiting

79 enrolled

Plasma cell

Multiple Myeloma

NCT02659293 2026-03-04

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Phase 3 Active not recruiting

180 enrolled

Plasma cell

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

Phase 3 Active not recruiting

250 enrolled

Plasma cell

Multiple Myeloma

NCT00602641 2026-03-03

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Active not recruiting

306 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT06963216 2026-02-27

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Phase 3 Recruiting

15 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

228 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

Clinical Trials

MagnetisMM-7

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

MagnetisMM-6

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

AURIGA

CARTITUDE-4

CARTITUDE-5

MajesTEC-3

A Study of Daratumumab

MonumenTAL-3

MajesTEC-7

MajesTEC-9

TRIlogy-4

TRIlogy-5

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

IFM2017_03

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

IFM2005-02

IFM/DFCI2009

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

EXCALIBER-RRMM

ElLen

SUCCESSOR-2

DREAMM-3

MAGNETISMM-5

iMMagine-3

MajesTEC-4

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

SUCCESSOR-1

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

CARTITUDE-6

LINKER-SMM2

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

CERVINO

MonumenTAL-6

DURGA-4

LINKER-MM3

KarMMa-9

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

(COBRA)

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression